[ad_1]
SAN CARLOS, Calif., Feb. 16, 2024 (GLOBE NEWSWIRE) — Iovance Biotherapeutics, Inc. (Nasdaq: IOVA) is a biotechnology company focused on innovating, developing and delivering novel polyclonal tumors to patients Infiltrating Lymphocyte (TIL) Therapy, a drug related to cancer, will host a conference call and live audio webcast to discuss the FDA approval announced earlier today on February 16, 2024 at 4:15 PM ET .
To participate in the conference call Q&A and live audio webcast, please register at https://register.vevent.com/register/BI0633b8a73e8b4c578bfed2a8ef37003e. To listen to live or archived webcasts, please register at https://edge.media-server.com/mmc/p/uqbbcfz4/. The live and archived webcast can be accessed from the investors section of the company’s website at IR.Iovance.com. The archived webcast will be available for one year.
About Iovance Biotherapeutics
Iovance Biotherapeutics aims to be a global leader in innovating, developing and delivering tumor-infiltrating lymphocyte (TIL) therapies to patients with cancer. We are pioneering a transformative approach to treating cancer that harnesses the body’s immune system’s ability to recognize and destroy different cancer cells in each patient’s body. The Iovance TIL platform has demonstrated promising clinical data in a variety of solid tumors. We are committed to continued innovation in cell therapies, including gene-edited cell therapies, that may extend and improve the lives of cancer patients. For more information, please visit www.iovance.com.
forward-looking statements
Certain matters discussed in this press release are “forward-looking statements” within the meaning of the private securities of Iovance Biotherapeutics, Inc. (the “Company,” “we,” or “our”) under the Litigation Reform Act of 1995 (“PSLRA” ). Without limiting the foregoing, in some cases we may use the terms “forecast,” “believe,” “potential,” “continue,” “estimate,” “anticipate,” “expect,” “plan” , terms such as “intend”, “forecast”, “guidance”, “outlook”, “may”, “could”, “could”, “will”, “should” or other words expressing uncertainty about future events or results Words intended to identify forward-looking statements. Forward-looking statements are based on assumptions and assessments based on management’s experience and perception of historical trends, current conditions, expected future developments and other factors deemed appropriate. The forward-looking statements in this press release are made as of the date of this press release, and we undertake no obligation to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors, many of which are beyond our control, that could cause actual results, levels of activity, performance, achievements and development to be materially affected. differ from those expressed or implied in these forward-looking statements. Important factors that could cause actual results, developments and business decisions to differ materially from forward-looking statements are described in the section titled “Risk Factors” in our filings with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and quarterly reports on Form 10-Q, including, but not limited to, the following material known and unknown risks and uncertainties inherent in our business: risks related to our ability to successfully commercialize our products, including AMTAGVI, we Obtain approval from the U.S. Food and Drug Administration (“FDA”), European Medicines Agency (“EMA”) or other regulatory authorities; the EMA or other regulatory authorities may not approve or may delay approval of our submissions for the treatment of metastatic melanoma risks to lifileucel’s Biologics License Application (“BLA”); the market acceptance of our products, including AMTAGVI, in the U.S. and other international markets and their potential pricing and/or payer reimbursement, if approved (with respect to our candidates) products), and whether such acceptance is sufficient to support the continued commercialization or development of our products, including AMTAGVI or product candidates; whether we are able to use third-party manufacturers or produce our therapies at our own facilities may Adverse effects on our commercial launch; results from clinical trials conducted with collaborators using different manufacturing processes may not be reflected in our sponsored trials; risks of the recent successful integration of the Proleukin acquisition; risks to our products, including AMTAGVI The risk that successful development or commercialization may not generate sufficient revenue from product sales and that we may not be profitable in the short term or at all; the risk that future competition or other market factors may adversely affect AMTAGVI’s commercial potential; the risk that our successful development, risks related to the timing and ability to submit, obtain or maintain approval or take other action with the FDA, EMA or other regulatory authorities for our product candidates; clinical trial results from our pivotal studies and cohorts and with the FDA, EMA or other regulatory authorities Whether the meeting can support registration studies and subsequent approval by the FDA, EMA or other regulatory agencies, including the risk that the planned single-arm phase 2 IOV-LUN-202 trial version may not support registration; preliminary and ongoing clinical trials or cohorts Interim clinical results (which may include efficacy and safety results) may not be reflected in our ongoing clinical trials or final analyzes of subgroups from these trials or other prior trials or cohorts; may be subject to regulatory approval by the FDA and other regulatory agencies Opinion to adjust the risks of enrollment in our trials and cohorts in these trials; The risk that changes in the care environment for cervical cancer patients may affect our clinical trials in this indication; We may need to comply with the FDA, EMA or other regulatory authorities the risk of conducting additional clinical trials or modifying ongoing or future clinical trials; our interpretation of clinical trial results or communications with the FDA, EMA or other regulatory authorities may differ from those of such regulatory authorities regarding such results or communications Interpretations differ (including from our prior discussions with the FDA regarding our non-small cell lung cancer clinical trial); clinical data from the ongoing AMTAGVI clinical trial will not be continued or replicated in ongoing or planned clinical trials, or may not be supported by regulatory authorities risks of approval or authorization renewals; the risk that unexpected charges could reduce our estimated cash balances and forecasts and increase our estimated capital requirements; the impact of the COVID-19 pandemic; and other factors, including general economic conditions and regulatory developments, are not within our control.
contact method
Iovance Biotherapeutics:
Sara Pellegrino, IRC
Senior Vice President, Investor Relations and Corporate Communications
650-260-7120 extension 264
Sara.Pellegrino@iovance.com
Jane Sanders
Senior Director, Investor Relations and Corporate Communications
267-485-3119
Jen.Saunders@iovance.com
[ad_2]
Source link